High Quality Samples Yield
Reliable Results
The growing importance of checkpoint inhibitors and other targeted therapies in
oncology underscores the need specific human biological samples
for translational and clinical research.
TriStar’s archived clinical samples include clinical follow up information
as well as IHC, NGS & RNAseq data
Our Customers can select samples from our biorepositories that are similar to
their clinical trial cohorts and potentially use our Real-World Data (RWD) sets
to correlate molecular information with responders & non-responders to
standard of care chemo, targeted and checkpoint inhibitor therapy.
A Single Entity for Samples and Contract Research
Unmatched Collection Of High-Density Tissue Microarrays with RNA/DNA
Our strategically collected repository & collaborations enables us to create scientifically relevant high-density TMAs for biomarker research
- Over 2.5 Million Archived Human Tumor Tissue Samples from Germany, Italy, Spain, U.K.
- Extensive Follow Up and Molecular Data. Treatment, Response, Survival Information
- Multi Tumor, Normal and Tumor-specific arrays,
- RNAscope pre-qualified TMAs
Quality Control
- 10% Buffered Formalin
- SOPs governing tissue processing, fixation, TMA Manufacture
- RNA (RIN), DNA Quality Control
- RNAscope QC Assay
Ethical Considerations
- Informed Donor Consent
- IRB/EC approval
- Fully Anonymized
- Compliant with Current U.S. (HIPAA), International & EU Regulations
Immuno-oncology
TriStar samples for immuno-oncology are selected based on advancing tumor margin, qualitative assessment of inflammatory infiltrate (low/moderate/high)and PDL1 staining (Ventana SP-263) and include:
- FFPE blocks from prevalent tumor types (NSCLC, Bladder, Head & Neck, Pancreatic, Gastric, TNBC, RCC etc.)
- PD-L1 control FFPE blocks (positive or negative) with matched double spun plasma and follow up data
We can conduct studies of customer specified immune signatures using prevalent platforms and compared if required to other randomly selected FFPE samples
Hematological Cancers
Hematological Cancers
Control FFPE Blocks
We screen thousands of FFPE blocks to identify ones that are positive or negative for selected markers.
Biomarkers include:
- EGFR Mutations (Exon 19, 21, Variants)
- KRAS Mutations (G12A, G12C, G12D, G12, G12V, G12R, G12S)
- TIM3, LAG3, OX40, GITR, IDO1, PD-L1, PD-1 (IHC)
- ALK (IHC)
- MSI (IHC)
- EGFR (amp)
- HER2 (IHC & CISH)
Integrated Solutions
We offer a highly cost effective and time-efficient CRO model by integrating our samples with in-house analytical capabilities
- IHC (Ventana Benchmark, Dako & Leica Bond)
- RNA Scope
- Sanger & NGS (Illumina MiSeq, ThermoFisher S5)
- RTPCR
- Assay Transfer and Development
- Target Profiling in Tumor & Normal Samples
Tissue Microarray Cascade
The cascade comprises one or more TMAs across 3 Levels or tiers and is designed to answer the following specific questions about Biomarker expression
- Which tumors and normal tissues is the Biomarker expressed in?
- Is the marker expressed in niche tumors?
- Is the marker prognostically relevant?
- Is there an association with relapse to SOC treatment?
Selective Biomarker Stratification
We have used sequencing and IHC in-house to stratify cohorts of samples for biomarker investigations and companion diagnostic development by our customers.
Examples
- CRC with KRAS, EGFR, NRAS, PIK3CA, BRAF, MSI
- Prostate cancers with PTEN (IHC & FISH).
- NSCLC, Bladder, Gastric, Small Bowel Carcinoma & RCC with known mismatch repair status (MSH-2, MSH-6, MLH-1, PMS-2 - Ventana IHC).
- NSCLC with PD-L1
Hematological Cancers
Our repository includes TMAs and FFPE blocks from the following indications;
- Non-Hodgkins Lymphoma
- Diffuse Large B-Cell Lymphoma (GCB/non-GCB)
- Follicular Lymphoma
- Mantle Cell Lymphoma
- Myelodysplastic Syndromes
- Chronic Lymphocytic Leukemia
- Follow up and Molecular Data
